News

US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
BioSpace14h
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
BioWorld4h
Abeona’s rare skin disease gene therapy approved by FDA
Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.
Fierce Pharma14h
Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease
Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
Skin-based test could improve diagnosis of debilitating neurodegenerative disease
Researchers at the University Health Network (UHN) and the University of Toronto have developed a skin-based test that can detect signature features of progressive supranuclear palsy (PSP), a rare ...
Crain's Cleveland Business10h
Cleveland company receives FDA approval for rare disease treatment
Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...
The Pharma Letter18h
New money for Nova to advance protein therapy for rare skin disorder
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer ...
First Cell-Based Gene Therapy Approved for Rare Skin Disorder
The US Food and Drug Administration (FDA) has approved the first cell-based gene therapy for a rare genetic skin disorder.
Stocktwits on MSN11h
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease
Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it announced that the U.S. Food ...
Medscape10h
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...